Oxford BioMedica PLC
LSE:OXB
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
167.2
445
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Oxford BioMedica PLC
Accrued Liabilities
Oxford BioMedica PLC
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Oxford BioMedica PLC
LSE:OXB
|
Accrued Liabilities
ÂŁ13.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
19%
|
||
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Accrued Liabilities
$27.5m
|
CAGR 3-Years
202%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Exscientia PLC
NASDAQ:EXAI
|
Accrued Liabilities
ÂŁ22.2m
|
CAGR 3-Years
123%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Accrued Liabilities
$38.7m
|
CAGR 3-Years
54%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
||
Immunocore Holdings PLC
NASDAQ:IMCR
|
Accrued Liabilities
ÂŁ121.2m
|
CAGR 3-Years
85%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
||
Genus PLC
LSE:GNS
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Oxford BioMedica PLC
Glance View
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
See Also
What is Oxford BioMedica PLC's Accrued Liabilities?
Accrued Liabilities
13.9m
GBP
Based on the financial report for Jun 30, 2024, Oxford BioMedica PLC's Accrued Liabilities amounts to 13.9m GBP.
What is Oxford BioMedica PLC's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
19%
Over the last year, the Accrued Liabilities growth was -18%. The average annual Accrued Liabilities growth rates for Oxford BioMedica PLC have been 2% over the past three years , 12% over the past five years , and 19% over the past ten years .